Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen
Whole-genome sequencing of 35,000 de-identified, diverse genomic DNA samples will begin this month SAN DIEGO, Jan. 9, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global biopharmaceutical…